ArticleCureus2025
Short-Term Outcomes of Laparoscopic Sleeve Gastrectomy for Weight Loss and Gastroesophageal Reflux Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retrospective analysis of the BariClip procedure: Clinical outcomes and complication profile.PloS one · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Laparoscopic sleeve gastrectomy (LSG), a novel bariatric technique, reduces stomach capacity to promote weight loss. It is increasingly preferred due to its lower risk and improved outcomes, particularly for obesity-associated hypertension and diabetes. LSG has also demonstrated effective weight loss. This study aimed to evaluate the short-term outcomes of LSG for treating obesity and gastroesophageal reflux disease (GERD). Methodology A prospective cohort study was conducted at Lady Reading Hospital-Medical Teaching Institute (LRH-MTI), Peshawar, from March 2023 to February 2024. A total of 280 patients (aged 18-60 years) were selected using a consecutive sampling technique. Weight loss was assessed using the percentage of total body weight loss (%TBWL) and excess weight loss (%EWL). GERD symptoms were evaluated using the GerdQ score. Statistical analyses, including paired t-tests and Chi-squared tests, were performed using SPSS version 26 (IBM Inc., Armonk, New York), with significance set at p<0.05. Results LSG achieved a 100% success rate with no major complications, an average surgery duration of 45 minutes, and a mean hospital stay of 2.5 days. At the 12-month follow-up, significant reductions in hypertension (p=0.032) and diabetes (p<0.012) were observed. Substantial weight loss (p=0.001) and a decrease in comorbidities were noted, while GERD symptom improvement was not statistically significant (p=0.348). Conclusion LSG is a promising intervention for weight loss and obesity-related comorbidities. It significantly improves hypertension and diabetes, although its impact on GERD requires further research. Longer follow-ups and diverse populations are recommended for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.